FDA Approves Tablet Form of Calquence.

THERAPEUTIC use of antineoplastic agents; DRUG approval; DRUG efficacy; CHRONIC lymphocytic leukemia; PHARMACEUTICAL encapsulation; CANCER relapse; UNITED States. Food & Drug Administration; TREATMENT effectiveness; GENETIC techniques; DOSAGE forms of drugs; PATIENT safety

The article discusses the FDA that has approved a tablet formulation of AstraZeneca's Calquence (acalabrutinib) for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and for patients with relapsed or refractory mantle cell lymphoma. The approval was based on results from the ELEVATE-PLUS trials, which showed the Calquence capsule and tablet formulations are bioequivalent, indicating the same efficacy and safety.